Virtus ETF Advisers’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-65,149
| Closed | -$47K | – | 437 |
|
|
2022
Q1 | $47K | Sell |
65,149
-3,866
| -6% | -$2.79K | 0.02% | 365 |
|
|
2021
Q4 | $156K | Buy |
69,015
+10,772
| +18% | +$24.3K | 0.06% | 337 |
|
|
2021
Q3 | $168K | Sell |
58,243
-3,041
| -5% | -$8.77K | 0.07% | 313 |
|
|
2021
Q2 | $232K | Sell |
61,284
-33,148
| -35% | -$125K | 0.1% | 237 |
|
|
2021
Q1 | $320K | Buy |
94,432
+1,661
| +2% | +$5.63K | 0.14% | 228 |
|
|
2020
Q4 | $260K | Buy |
92,771
+65,225
| +237% | +$183K | 0.11% | 298 |
|
|
2020
Q3 | $69K | Sell |
27,546
-3,747
| -12% | -$9.39K | 0.04% | 322 |
|
|
2020
Q2 | $425K | Sell |
31,293
-24,977
| -44% | -$339K | 0.2% | 176 |
|
|
2020
Q1 | $427K | Sell |
56,270
-8,206
| -13% | -$62.3K | 0.18% | 190 |
|
|
2019
Q4 | $407K | Buy |
64,476
+2,846
| +5% | +$18K | 0.07% | 247 |
|
|
2019
Q3 | $242K | Sell |
61,630
-3,433
| -5% | -$13.5K | 0.05% | 219 |
|
|
2019
Q2 | $315K | Buy |
65,063
+31,549
| +94% | +$153K | 0.07% | 201 |
|
|
2019
Q1 | $274K | Sell |
33,514
-4,669
| -12% | -$38.2K | 0.58% | 66 |
|
|
2018
Q4 | $211K | Sell |
38,183
-3,854
| -9% | -$21.3K | 0.04% | 175 |
|
|
2018
Q3 | $371K | Sell |
42,037
-30,371
| -42% | -$268K | 0.04% | 171 |
|
|
2018
Q2 | $723K | Buy |
72,408
+21,946
| +43% | +$219K | 0.64% | 90 |
|
|
2018
Q1 | $481K | Buy |
50,462
+27,003
| +115% | +$257K | 0.42% | 112 |
|
|
2017
Q4 | $349K | Buy |
23,459
+440
| +2% | +$6.55K | 0.44% | 88 |
|
|
2017
Q3 | $453K | Buy |
23,019
+2,106
| +10% | +$41.4K | 0.06% | 97 |
|
|
2017
Q2 | $301K | Buy |
+20,913
| New | +$301K | 0.04% | 123 |
|
|
2016
Q4 | – | Sell |
-29,590
| Closed | -$268K | – | 178 |
|
|
2016
Q3 | $268K | Hold |
29,590
| – | – | 0.13% | 116 |
|
|
2016
Q2 | $221K | Buy |
29,590
+8,160
| +38% | +$60.9K | 0.16% | 124 |
|
|
2016
Q1 | $193K | Buy |
+21,430
| New | +$193K | 0.27% | 91 |
|